Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 758

Similar articles for PubMed (Select 18395777)

1.

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.

Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS.

Gynecol Oncol. 2008 Jun;109(3):370-6. doi: 10.1016/j.ygyno.2008.02.006. Epub 2008 Apr 18.

PMID:
18395777
2.

Racial disparities in surgical treatment and survival of epithelial ovarian cancer in United States.

Chan JK, Zhang M, Hu JM, Shin JY, Osann K, Kapp DS.

J Surg Oncol. 2008 Feb 1;97(2):103-7.

PMID:
17979133
3.

Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.

Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, Young RC; Gynecologic Oncology Group.

Cancer. 2008 May 15;112(10):2202-10. doi: 10.1002/cncr.23390.

4.

Association of lymphadenectomy and survival in stage I ovarian cancer patients.

Chan JK, Munro EG, Cheung MK, Husain A, Teng NN, Berek JS, Osann K.

Obstet Gynecol. 2007 Jan;109(1):12-9.

PMID:
17197582
5.

Patterns and progress in ovarian cancer over 14 years.

Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, Berek JS, Osann K.

Obstet Gynecol. 2006 Sep;108(3 Pt 1):521-8.

PMID:
16946210
6.

The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.

Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL.

Gynecol Oncol. 2000 Apr;77(1):55-65.

PMID:
10739691
7.

Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women.

Matthews RP, Hutchinson-Colas J, Maiman M, Fruchter RG, Gates EJ, Gibbon D, Remy JC, Sedlis A.

Gynecol Oncol. 1997 May;65(2):206-12.

PMID:
9159326
8.

The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.

Chan JK, Tian C, Fleming GF, Monk BJ, Herzog TJ, Kapp DS, Bell J.

Gynecol Oncol. 2010 Mar;116(3):301-6. doi: 10.1016/j.ygyno.2009.10.073. Epub 2009 Nov 28.

PMID:
19945740
9.

Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women.

Zhang M, Cheung MK, Shin JY, Kapp DS, Husain A, Teng NN, Berek JS, Osann K, Chan JK.

Gynecol Oncol. 2007 Feb;104(2):396-400. Epub 2006 Oct 9.

PMID:
17030354
10.

Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma.

Tammela J, Geisler JP, Eskew PN Jr, Geisler HE.

Eur J Gynaecol Oncol. 1998;19(5):438-40.

PMID:
9863906
12.

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers.

Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK.

Br J Cancer. 2006 Mar 13;94(5):642-6.

13.

Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.

Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, Papadimitriou C, Rodolakis A, Vlahos G, Dimopoulos MA.

Cancer. 2010 Mar 15;116(6):1462-8. doi: 10.1002/cncr.24915.

14.

Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.

Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; Gynecologic Cancer InterGroup.

Int J Gynecol Cancer. 2010 Aug;20(6):945-52. doi: 10.1111/IGC.0b013e3181dd0110. Review.

PMID:
20683400
15.

HSP27 in patients with ovarian carcinoma: still an independent prognostic indicator at 60 months follow-up.

Geisler JP, Tammela JE, Manahan KJ, Geisler HE, Miller GA, Zhou Z, Wiemann MC.

Eur J Gynaecol Oncol. 2004;25(2):165-8.

PMID:
15032273
16.

Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0).

Sakuragi N, Yamada H, Oikawa M, Okuyama K, Fujino T, Sagawa T, Fujimoto S.

Gynecol Oncol. 2000 Nov;79(2):251-5.

PMID:
11063653
17.

Clinicopathologic analysis of early-stage sporadic ovarian carcinoma.

Leitao MM Jr, Boyd J, Hummer A, Olvera N, Arroyo CD, Venkatraman E, Baergen RN, Dizon DS, Barakat RR, Soslow RA.

Am J Surg Pathol. 2004 Feb;28(2):147-59.

PMID:
15043303
18.

Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.

Storey DJ, Rush R, Stewart M, Rye T, Al-Nafussi A, Williams AR, Smyth JF, Gabra H.

Cancer. 2008 May 15;112(10):2211-20. doi: 10.1002/cncr.23438.

19.

[Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].

Shao HL, Shen DH, Xue WC, Li Y, Yu YZ.

Zhonghua Fu Chan Ke Za Zhi. 2007 Apr;42(4):227-32. Chinese.

PMID:
17631760
20.

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N.

Obstet Gynecol. 2002 Aug;100(2):281-7.

PMID:
12151151
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk